Molbio Diagnostics IPO: ₹939.70 Cr Debut Aug 2026
Scientist operating a diagnostic device in a laboratory
Key Highlights
Molbio Diagnostics IPO opens Aug 10-12, 2026, aiming ₹939.70 Cr. Price band ₹768-₹807. Discover details on this key diagnostic solutions debut.
Molbio Diagnostics is set to launch its (IPO), aiming to raise approximately ₹939.70 crores. The subscription window runs from August 10 to August 12, 2026.
Key IPO Details
- Total IPO Size: ₹939.70 crores
- Component: ₹200 crores
- (OFS): Up to 91,66,000 equity shares
- : ₹768 to ₹807 per equity share
- : ₹1 per share
- Minimum : 18 shares (₹14,526)
Investor allocation is structured with 50% for (QIB), 15% for Non-Institutional Investors (), and 35% for Retail Investors.
IPO Timeline
- Allotment Finalization: August 13, 2026
- Refund Processing: August 14, 2026
- Shares Credited to Demat: August 14, 2026
- and Listing: August 17, 2026
Molbio Diagnostics specializes in rapid, accurate point-of-care (POC) diagnostic solutions. Their flagship product is the portable Truenat PCR testing platform, developed through its subsidiary Bigtec Labs.
Financial Performance (FY2025-2026)
- 2025: ₹1027.94 crores
- Revenue 2026: ₹1455.17 crores
- Profits 2025: ₹138.58 crores
- Profits 2026: ₹164.14 crores
Based on these financials, the IPO is considered suitable for long-term investment. include Chandrasekhar Bhaskaran Nair and Sriram Natarajan, among others, with a post-IPO holding of 37.69%.
IPO Proceeds Utilization
The proceeds from the IPO are earmarked for several key initiatives. A total of ₹118.08 crores will fund capital expenditure for a new R&D facility, Center of Excellence, and connected office space.
- Plant, Machinery, Equipment for Goa and Visakhapatnam: ₹79.04 crores
- General Corporate Purposes